Insider Selling: Jess Roper Unloads 8,000 Shares of DexCom Stock (DXCM)
DexCom (NASDAQ:DXCM) CFO Jess Roper unloaded 8,000 shares of the stock on the open market in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $39.17, for a total transaction of $313,360.00. Following the transaction, the chief financial officer now directly owns 87,786 shares in the company, valued at approximately $3,438,578. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
DexCom (NASDAQ:DXCM) traded up 1.72% during mid-day trading on Wednesday, hitting $39.89. 795,479 shares of the company’s stock traded hands. DexCom has a 1-year low of $19.93 and a 1-year high of $49.83. The stock has a 50-day moving average of $33.76 and a 200-day moving average of $37.61. The company’s market cap is $2.988 billion.
DexCom (NASDAQ:DXCM) last released its earnings data on Thursday, May 1st. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.33 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on DXCM shares. Analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $33.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. DexCom presently has a consensus rating of “Hold” and an average target price of $38.00.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.